Welcome to the Machine: What Life Science Companies Need to Know About FDA’s Stance on AI

Event Details

As evidenced by FDA’s recent discussion paper on artificial intelligence (“AI”) and other guidance documents discussing the development of drug, biological, and medical device products, the burgeoning technology continues to be at the forefront of FDA’s focus. Please join AGG Food & Drug attorneys Alan Minsk and Laura Dona for a complimentary webinar delving into FDA’s regulation of AI-driven technologies as it relates to product development and manufacturing.

During the webinar, Alan and Laura will provide:

• Insight into FDA’s statements on AI, such as FDA’s discussion paper and guidance documents
• A look at cybersecurity risks
• Recommendations to maximize the AI opportunity/minimize the regulatory risks

There will be an opportunity for Q&A at the end of this webinar.

Credits: 1 hour of CLE credit is approved by the State Bar of Georgia

To enhance your webinar experience with us, please make sure to access the webinar from outside of a VPN and close out of all other streaming services. The webinar is best viewed on a desktop or laptop computer. The recommended browser is Google Chrome.

Please click here to perform an automatic system check to confirm your system is compatible with the webinar.

Please click here to view the GoToWebinar attendee guide.

Recording

To watch a recording of the webinar, please click here.